Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Complexed prostate-specific antigen for the diagnosis of biochemical recurrence after radical prostatectomy.

Parsons JK, Partin AW, Trock B, Bruzek DJ, Cheli C, Sokoll LJ.

BJU Int. 2007 Apr;99(4):758-61.

2.

Association between serum adiponectin, and pathological stage and grade in men undergoing radical prostatectomy.

Freedland SJ, Sokoll LJ, Platz EA, Mangold LA, Bruzek DJ, Mohr P, Yiu SK, Partin AW.

J Urol. 2005 Oct;174(4 Pt 1):1266-70.

PMID:
16145390
3.

Serum leptin and pathological findings at the time of radical prostatectomy.

Freedland SJ, Sokoll LJ, Mangold LA, Bruzek DJ, Mohr P, Yiu SK, Epstein JI, Partin AW.

J Urol. 2005 Mar;173(3):773-6.

PMID:
15711267
4.

Comparison of total prostate-specific antigen and derivative levels in a screening population of black, white, and Korean-American men.

Park J, Sokoll LJ, Bruzek DJ, Mangold L, Gurganus R, Khan MA, Partin AW, Chan DW, Veltri RW.

Clin Prostate Cancer. 2003 Dec;2(3):173-6.

PMID:
15040861
5.

Standardization of two immunoassays for human glandular kallikrein 2.

Haese A, Vaisanen V, Finlay JA, Pettersson K, Rittenhouse HG, Partin AW, Bruzek DJ, Sokoll LJ, Lilja H, Chan DW.

Clin Chem. 2003 Apr;49(4):601-10.

6.

Prospective evaluation of percent free-PSA and complexed-PSA for early detection of prostate cancer.

Partin AW, Brawer MK, Subong EN, Kelley CA, Cox JL, Bruzek DJ, Pannek J, Meyer GE, Chan DW.

Prostate Cancer Prostatic Dis. 1998 Jun;1(4):197-203.

8.

Short-term stability of the molecular forms of prostate-specific antigen and effect on percent complexed prostate-specific antigen and percent free prostate-specific antigen.

Sokoll LJ, Bruzek DJ, Dua R, Dunn W, Mohr P, Wallerson G, Eisenberger M, Partin AW, Chan DW.

Urology. 2002 Oct;60(4 Suppl 1):24-30.

PMID:
12384159
9.

Complexed prostate-specific antigen as a staging tool for prostate cancer: a prospective study in 420 men.

Sokoll LJ, Mangold LA, Partin AW, Epstein JI, Bruzek DJ, Dunn W, Mohr P, Wallerson G, Chan DW.

Urology. 2002 Oct;60(4 Suppl 1):18-23.

PMID:
12384158
10.

Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer.

Brawer MK, Cheli CD, Neaman IE, Goldblatt J, Smith C, Schwartz MK, Bruzek DJ, Morris DL, Sokoll LJ, Chan DW, Yeung KK, Partin AW, Allard WJ.

J Urol. 2000 May;163(5):1476-80.

PMID:
10751861
11.

Hybritech total and free prostate-specific antigen assays developed for the Beckman Coulter access automated chemiluminescent immunoassay system: a multicenter evaluation of analytical performance.

Laffin RJ, Chan DW, Tanasijevic MJ, Fischer GA, Markus W, Miller J, Matarrese P, Sokoll LJ, Bruzek DJ, Eneman J, Nelson J, Bray KR, Huang J, Loveland KG.

Clin Chem. 2001 Jan;47(1):129-32. No abstract available.

12.

Clinical evaluation comparing AxSYM CA 15-3, IMx CA 15-3 and Truquant BRTM RIA.

Lynch DM, Rogers PE, Love JC, Salkas MJ, Skarphol KA, Gross ME, Lu MG, Petrides VH, Bruzek DJ, Cox JL, Jones KA, Kelley CA, Chan DW.

Tumour Biol. 1998;19(6):421-38.

PMID:
9817970
13.

Influence of radical prostatectomy on serum hormone levels.

Miller LR, Partin AW, Chan DW, Bruzek DJ, Dobs AS, Epstein JI, Walsh PC.

J Urol. 1998 Aug;160(2):449-53.

PMID:
9679896
14.

Identifying markers for pancreatic cancer by gene expression analysis.

Zhou W, Sokoll LJ, Bruzek DJ, Zhang L, Velculescu VE, Goldin SB, Hruban RH, Kern SE, Hamilton SR, Chan DW, Vogelstein B, Kinzler KW.

Cancer Epidemiol Biomarkers Prev. 1998 Feb;7(2):109-12.

15.

Bayer Immuno 1 PSA Assay: an automated, ultrasensitive method to quantitate total PSA in serum.

Morris DL, Dillon PW, Very DL, Ng P, Kish L, Goldblatt JL, Bruzek DJ, Chan DW, Ahmed MS, Witek D, Fritsche HA, Smith C, Schwartz D, Schwartz MK, Noteboom JL, Vessella RL, Yeung KK, Allard WJ.

J Clin Lab Anal. 1998;12(1):65-74.

16.

Molecular forms of prostate-specific antigen and human kallikrein 2 (hK2) in urine are not clinically useful for early detection and staging of prostate cancer.

Pannek J, Rittenhouse HG, Evans CL, Finlay JA, Bruzek DJ, Cox JL, Chan DW, Subong EN, Partin AW.

Urology. 1997 Nov;50(5):715-21.

PMID:
9372881
17.

The value of prostate-specific antigen in the management of localized prostatic cancer.

Walsh PC, Oesterling JE, Epstein JI, Bruzek DJ, Rock RC, Chan DW.

Prog Clin Biol Res. 1989;303:27-33.

PMID:
2476820
18.

Monitoring breast cancer with CA 549.

Chan DW, Beveridge RA, Bruzek DJ, Damron DJ, Bray KR, Gaur PK, Ettinger DS, Rock RC.

Clin Chem. 1988 Oct;34(10):2000-4.

19.

Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy.

Oesterling JE, Chan DW, Epstein JI, Kimball AW Jr, Bruzek DJ, Rock RC, Brendler CB, Walsh PC.

J Urol. 1988 Apr;139(4):766-72.

PMID:
2451037
20.
21.

Prostate-specific antigen as a marker for prostatic cancer: a monoclonal and a polyclonal immunoassay compared.

Chan DW, Bruzek DJ, Oesterling JE, Rock RC, Walsh PC.

Clin Chem. 1987 Oct;33(10):1916-20.

Supplemental Content

Loading ...
Support Center